Mark Murcko is Director at Relay Therapeutics, Inc. (RLAY). They have made 2 open-market trades across 1 company since 2020, most recently 2022-09-08.
CIK 0001816130
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $500K since 2020, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RLAY | 996,952 | $16.3M |
Shares reported on the most recent Form 4, priced at the 2022-09-08 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.